$ABEO

Alvino Mark sold $88K of ABEO

Alvino Mark sold 15,000 shares of ABEONA THERAPEUTICS INC. (ABEO) at $5.86 on 2026-09-01.

Original reporting
SEC EDGAR · Alvino Mark
Published Sep 1, 2026, 9:48 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ABEO
Neutral
medium confidence
Mentioned
$ABEO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABEONeutralLow
01

Why it matters

The disclosed sale provides fresh, primary information but its modest size limits trading relevance.

02

Market read

A routine insider sale with limited market impact; primarily of interest to short‑term traders monitoring insider activity.

03

What to watch

Potential upcoming clinical data releases could outweigh the impact of this sale.

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-01

Background

Form 4 filing from SEC EDGAR reporting a director's stock sale.

Company-level read

Ticker impact

$ABEONeutralMedium confidence
Context

Director Alvino Mark sold 15,000 shares for $87,966, reducing his stake to 62,065 shares.

Expected impact

Minor short‑term dip or flat price action.

Evidence & confidence

The transaction size (~$88k) is small relative to market cap; insider sales of this magnitude rarely trigger large moves.

Market effects

None significant; biotech sector unchanged.

No regional effect.

Low; isolated insider transaction.

Counterpoint

Even small insider sales can precede larger moves if the insider has private concerns.

Key entities

  • Abeona Therapeutics Inc.

    Biopharmaceutical company developing gene‑editing therapies.

  • Alvino Mark

    Director of Abeona Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ABEOMed

Abeona Therapeutics Swings To Q2 Net Loss; Shares Plunge

Abeona Therapeutics (ABEO) reported Q2 2026 results showing a swing to a net loss of $20.19M, or $0.35/share, versus net income of $108.83M, or $1.71/share, a year earlier largely due to a $152.37M priority review voucher gain. Q2 revenue rose to $11.38M from $0.40M. Cash totaled $146.8M as of June 30. ZEVASKYN treated 5 patients in Q2.

$ABEOMedAI 8/10

Why is Abeona Therapeutics stock slumping today?

Abeona Therapeutics (ABEO) shares fell 15.8% pre-open after it reported Q2 2026 results. The company posted a loss of 35 cents per share versus a year-earlier profit of $1.71, and revenue of $11.4M versus an estimated $12.2M. Revenue recognition for ZEVASKYN was limited by a manufacturing batch yield shortfall.

$ABEOMed

ABEONA THERAPEUTICS INC. (ABEO): Results of Operations and Financial Condition

ABEONA THERAPEUTICS INC. (ABEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Abeona Therapeutics ® Reports Second Quarter 2026 Results and Provides Business Update - Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million – - Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since lau

$ABEOMedAI 8/10

A new CMS payment could help Medicare patients access ZEVASKYN

Abeona Therapeutics (Nasdaq: ABEO) said CMS granted ZEVASKYN (prademagene zamikeracel) NTAP status under the FY2027 Hospital Inpatient Prospective Payment System rule. Abeona said NTAP adds supplemental Medicare reimbursement for technologies showing substantial clinical improvement. The company also reiterated ZEVASKYN’s safety risks, including potential cancer risk and serious allergic reactions.